Radient Pharm (RPC $0.20 0.05) expects to see benefits from previously
undisclosed new major partnership in India.
In an interview, Dr. Umesh Bhatia, Ph.D, senior advisor for the Onko-Sure for
Radient Pharmaceuticals' operations in India, has revealed that his group has
secured a major new partnership that should clearly benefit Radient and is
expected to impact the company's bottom line.






